SGLT2 Inhibitors' Cardiovascular Benefits In Individuals Without Diabetes, Heart Failure, And/Or Chronic Kidney Disease: A Systematic Review.

Despite the growing body of evidence regarding the beneficial cardiovascular effects of sodium-glucose co-transporter-2 (SGLT2) inhibitors, clinical data in individuals without diabetes, heart failure (HF), and/or chronic kidney disease (CKD) is limited. A systematic review of the literature was conducted in PubMed, Scopus, Web of Science, Cochrane Library, and Google Scholar, from database inception until May 4, 2023, to explore new evidence of SGLT2 inhibitors' cardiovascular benefits in individuals without diabetes, HF, and/or CKD. A total of 1156 individuals from 14 studies (13 randomized controlled trials and one non-randomized study) were included. The results showed the benefits of SGLT2 inhibitors on blood pressure (BP), weight, and body mass index (BMI) in this population with an acceptable safety profile. The current evidence supports the potential role of SGLT2 inhibitors as primary prevention in individuals without diabetes, HF, and/or CKD. This review may shed light on the use of SGLT2 inhibitors in conditions such as stage A HF and metabolic syndrome. The literature trend is going toward uncovering SGLT2 inhibitors' role in stage B HF, different types of myocardial infarction (MI), and cardiac arrhythmias. This article is protected by copyright. All rights reserved.